Phase 2 Interstitial Lung Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with Idiopathic Pulmonary Fibrosis (IPF) — a type of long-term lung scarring disease — within the last 7 years, where the diagnosis is supported by a specific type of lung scan (called a high-resolution CT scan) taken within the past 12 months, and that scan shows a particular pattern of lung damage consistent with IPF (confirm with trial site)
Who may not be able to join:
- People who have had a stroke in the 6 months before the screening visit
- People who have other significant lung problems that the trial doctor considers clinically important (confirm with trial site)
- People who have had any type of cancer in the last 5 years, unless it was a type of common skin cancer (non-melanoma) that was successfully treated, or a very early-stage localised cervical condition that was successfully treated
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 844-663-3742
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Absolute Change From Baseline in Forced Vital Capacity (FVC) (mL); Percentage of Participants with Adverse Events (AE)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.